Maharashtra FDA cancels Cipla Pune licences
Analysis based on 52 articles · First reported Aug 28, 2026 · Last updated Aug 29, 2026
The cancellation of Cipla's Pune C&F drug sale licences may disrupt distribution of its products in Maharashtra, potentially affecting short-term sales and logistics. The regulatory action could raise compliance concerns for Cipla, but the impact is likely limited given the scale of the facility and the company's overall operations.
The India — Maharashtra Food and Drug Administration (FDA) cancelled the drug sale licences of Cipla Pharma & Life Sciences Ltd's Carry and Forwarding (C&F) facility at Wadki, Pune, effective August 27, 2026. The action followed inspections that found unauthorised promotional text on the packaging of Reactin Plus Tablets, a Schedule H prescription medicine, describing it as an 'analgesic and antipyretic'. The FDA seized stock worth over Rs 11 lakh and ordered a recall, but found the company's compliance with recall directions inadequate. Further inspections revealed storage deficiencies, including medicines stored directly on the floor, inadequate pallet and rack facilities, discrepancies between physical and computerised stock records, and lapses in handling expired medicines. FDA Commissioner Tukaram Mundhe emphasised a strict approach to violations affecting drug safety and public health.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard